News sentiment score by Company Name and Selected Events categories in the biotechnology industry, May 01-14
The visual represents the news sentiment score by company name and selected events categories (regulatory decisions and trial results) in the biotechnology industry, May 01-14
In the past 14 days, companies within the biotechnology industry got regulatory decisions related to new drugs and medical treatments as well as some companies report results of clinical trials.
Each circle represents the companies that got news event, the size of each company’s circle represents the news sentiment score. The bigger the company’s circle the higher the sentiment score.
For example: On May 1, 2018, BioCryst announced that the European Medicines Agency (“EMA”) has approved peramivir with the brand name of ALPIVABTM, a single intravenous infusion for the treatment of uncomplicated influenza in adults and children from the age of 2 years. The EMA approval of ALPIVAB under the centralized licensing procedure provides marketing authorization for all 28-member states of the European Union, Norway and Iceland.
The company’s current news sentiment score is 0.76 (above 0.5 is consider bullish) and the stock price jump 12.7% from the announcement.
In the trial results circle, Motif Bio plc reports on May 1 that its Iclaprim met the primary endpoint – the REVIVE-2 study was a global Phase 3 trial evaluating iclaprim in patients with ABSSSI. As previously reported, the study met its primary endpoint of non-inferiority (NI) (10% margin) compared to vancomycin, the current standard of care, at the early time point (ETP), 48 to 72 hours after the start of administration of the study drug, in the intent-to-treat (ITT) patient population. Iclaprim also achieved NI (10% margin) at the test of cure (TOC) endpoint, 7 to 14 days after study drug discontinuation. The company current news sentiment score is 0.76 (above 0.5 is consider bullish) and the stock price jump 12.7% from the announcement.
The company’s current news sentiment score is 0.69 (above 0.5 is consider bullish) and the stock price jump 23.08% from the announcement.
Insights for the data-driven investor’s
Big data provider for financial services. Using big data technology to reveal hidden insights from text within tens of thousands of news articles every day and by presenting this data in visually compelling with interactive dashboards on your PC, mobile and real-time API.
Filter out the noise, from +12,000 news items per day, receive and analyze only news items that matter to your strategy, that moves markets, in real-time 24/7.
We use big data, to aggregate in real-time more than 12,000 news items per day. Next, we filter the news using text and sentiment analysis of bullish and bearish keywords and phrases. It’s taken us less than a minute from the news release, analyze the news and send it.
We generate news sentiment score based on a machine-readable dataset and compare it with actual performance with interactive dashboards. Add any datasets to leverage your analysis even further in a secure environment.
Leverage on Google search capabilities and financial social media to find press releases and news stories on companies, currencies, commodities, central banks, cryptocurrency, macroeconomics, and governments 24/7.
Our data is presenting on interactive dashboards on the web or on your phone, get alerts when data changes, and drill into details. Furthermore, combine your data with ours to get more insights. Alpha is at your fingertips.
Low latency API, clients plug in our API into their existing application to display our data.
(Views and recommendations given in this section are for research purposes only. Please consult your financial adviser before taking any position in the stock/s or currencies mentioned.) Neither First to invest. nor any of its officers, employees, representatives, agents or independent contractors are, in such capacities, licensed financial advisors, registered investment advisers or registered broker-dealers. First to invest does not provide investment or financial advice or make investment recommendations. Nothing contained in this communication constitutes a solicitation, recommendation, promotion, endorsement or offer by First to invest of any particular security, transaction or investment. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers